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MaBACKGROUND Altered intestinal function is prevalent in patients with heart failure (HF), but its role in adverse
outcomes is unclear.
OBJECTIVES This study investigated the potential pathophysiological contributions of intestinal microbiota in HF.
METHODS We examined the relationship between fasting plasma trimethylamine-N-oxide (TMAO) and all-cause
mortality over a 5-year follow-up in 720 patients with stable HF.
RESULTS The median TMAO level was 5.0 mM, which was higher than in subjects without HF (3.5 mM; p < 0.001).
There was modest but signiﬁcant correlation between TMAO concentrations and B-type natriuretic peptide (BNP) levels
(r ¼ 0.23; p < 0.001). Higher plasma TMAO levels were associated with a 3.4-fold increased mortality risk. Following
adjustments for traditional risk factors and BNP levels, elevated TMAO levels remained predictive of 5-year mortality risk
(hazard ratio [HR]: 2.2; 95% CI: 1.42 to 3.43; p < 0.001), as well as following the addition of estimated glomerular
ﬁltration rate to the model (HR: 1.75; 95% CI: 1.07 to 2.86; p < 0.001).
CONCLUSIONS High TMAO levels were observed in patients with HF, and elevated TMAO levels portended higher
long-term mortality risk independent of traditional risk factors and cardiorenal indexes. (J Am Coll Cardiol
2014;64:1908–14) © 2014 by the American College of Cardiology Foundation.m the *Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio;
epartment of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio; and the zDepartment of
thematics, Cleveland State University, Cleveland, Ohio. This research was supported by grants from the National Institutes of
alth (NIH) and the Ofﬁce of Dietary Supplements (R01HL103866, P20HL113452). The GeneBank study was supported by NIH
nts P01HL076491, P01HL098055, and R01HL103931, and the Cleveland Clinic Clinical Research Unit of the Case Western
serve University CTSA (UL1TR 000439). Dr. Wang was partially supported by an American Heart Association Scientist Devel-
ment Grant (12SDG12050473). Dr. Hazen was partially supported by a gift from the Leonard Krieger endowment and the
undation LeDucq. Dr. Tang has received investigator-initiated research grant support from Abbott Laboratories, with no per-
al ﬁnancial payments. Drs. Wang and Levison are named as co-inventors on pending patents held by the Cleveland Clinic
ating to cardiovascular diagnostics and have the right to receive royalty payment for inventions or discoveries related to
diovascular diagnostics from LipoScience, Inc. Dr. Hazen is named as a co-inventor on pending patents held by the Cleveland
nic relating to cardiovascular diagnostics; has received consulting fees from Abbott Diagnostics, Cleveland Heart Lab, Esperion,
ly, LipoScience, Inc., Merck & Co., Procter & Gamble, and Pﬁzer; has received research funds from Abbott Diagnostics,
veland Heart Lab, LipoScience, Inc., Procter & Gamble, Pﬁzer, and Takeda; and has the right to receive royalty payments for
entions or discoveries related to cardiovascular diagnostics or therapeutics from Cleveland Heart Lab, Esperion, Frantz Bio-
rkers, and LipoScience, Inc. All other authors have reported that they have no relationships relevant to the contents of this
per to disclose.
ten to this manuscript’s audio summary by JACC Editor-in-Chief Dr. Valentin Fuster.
u can also listen to this issue’s audio summary by JACC Editor-in-Chief Dr. Valentin Fuster.
nuscript received December 2, 2013; revised manuscript received February 10, 2014, accepted February 17, 2014.
AB BR E V I A T I O N S
AND ACRONYM S
BNP = B-type natriuretic
peptide
eGFR = estimated glomerular
ﬁltration rate
HDL-C = high-density
lipoprotein cholesterol
HF = heart failure
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1909T here is increasing recognition that the gastro-intestinal system represents an often over-looked contributor to the pathogenesis of
heart failure (HF) syndrome and its adverse complica-
tions (1,2). Normally, intestinal barrier function
is maintained by a well-balanced intestinal microbial
community, intact tight junctions in the mucosa,
normal mucosal immunity, and normal sodium
and water homeostasis. With HF and associatedSEE PAGE 1915
hsCRP = high-sensitivity
C-reactive protein
TMAO = trimethylamine-
N-oxide
splanchnic circulation congestion, bacterial translo-
cation can occur due to altered intestinal barrier func-
tion, bacterial overgrowth, and impaired host
defense, leading to endotoxemia that in turn can
contribute to systemic inﬂammation. Several of these
features of altered intestinal function have been
observed in patients with HF (3,4). Meanwhile, pro-
gressive venous congestion in subsets of patients
with signiﬁcant congestive signs and symptoms may
lead to unwanted consequences of abdominal conges-
tion, including adverse impact on drug absorption
and pharmacokinetics (5,6), and renal glomerular
and tubular dysfunction resulting from raised intra-
abdominal pressures (7,8).
Intestinal microbiota are implicated in the re-
gulation of multiple host metabolic pathways that
contribute to phenotypes such as obesity and in-
sulin resistance (9). Our group has recently described
a mechanistic link between intestinal microbe-
dependent generation of trimethylamine-N-oxide
(TMAO) and increased risk for future cardiovascular
events (death, myocardial infarction, and stroke)
by a pathway involving dietary nutrients such as
phosphatidylcholine, choline, and carnitine (10–12).
In chronic systolic HF, the relationship between
the intestinal microbiota-generated metabolite TMAO
and both cardiorenal indexes and long-term clinical
prognosis has not been examined. We sought to
investigate the relationship between fasting plasma
TMAO levels and long-term clinical prognosis in pa-
tients with stable HF undergoing cardiac evaluation,
particularly in relation with established prognostic
markers (B-type natriuretic peptide [BNP] and esti-
mated glomerular ﬁltration rate [eGFR]).
METHODS
STUDY POPULATION. We prospectively enrolled pa-
tients with stable cardiac disease seen at the Cleve-
land Clinic between 2001 and 2007 with a history of
HF undergoing elective, nonurgent coronary angio-
graphic evaluation. We excluded those patients who
had experienced acute coronary syndrome within thepreceding 30 days (cardiac troponin I #0.03
ng/ml). All-cause mortality was prospectively
tracked for 5 years with the Social Security
Death Index and medical chart review and
conﬁrmed by follow-up contact. We also
performed a cross-sectional comparison of
TMAO levels between our cohort of patients
with stable systolic HF and an independent
set of 300 prospectively recruited, apparently
healthy subjects without known cardiac dis-
ease from a health-screening program at
various locations across Cleveland, Ohio.
All subjects for all studies gave written
informed consent approved by the Cleveland
Clinic Institutional Review Board.
STUDY DESIGN AND ASSAY MEASUREMENTS. This
is a single-center, prospective cohort study approved
by the Cleveland Clinic Institutional Review Board.
After informed consent was obtained from all pa-
tients, fasting plasma blood samples were collected
using EDTA tubes, which were then immediately
processed and frozen at 80C until analysis. Fasting
plasma TMAO levels were quantiﬁed by stable isotope
dilution liquid chromatography with online tandem
mass spectrometry (LC/MS/MS) on an APi 500 triple
quadruple mass spectrometer (AB SCIEX, Framing-
ham, Massachusetts), as previously described (10–12).
BNP, high-sensitivity C-reactive protein (hsCRP),
fasting lipid panel, uric acid, and serum creatinine
were measured using the Architect ci8200 platform
(Abbott Laboratories, Abbott Park, Illinois). Serum
arylesterase activity was measured in the same plat-
form as previously described (13).
STATISTICAL ANALYSES. Continuous variables are
summarized as mean  SD if normally distributed and
median (interquartile range [IQR]) if not normally
distributed. The Student t test or Wilcoxon-rank
sum test for continuous variables and chi-square
test for categorical variables were employed to ex-
amine between-group differences. Spearman corre-
lation was used to examine the associations between
TMAO and other laboratory measurements. Kaplan-
Meier survival plots and Cox proportional hazards
analysis were used to determine hazard ratio (HR)
and 95% CI for all-cause mortality stratiﬁed according
to TMAO as a continuous variable (log-transformed
per SD increase), as well as according to quartiles.
Adjustments were made for individual traditional
risk factors, including age, sex, systolic blood pres-
sure, low-density lipoprotein cholesterol, high-
density lipoprotein cholesterol (HDL-C), smoking,
diabetes mellitus, and BNP, to predict all-cause mor-
tality risks. Net reclassiﬁcation and area under the
TABLE 1 Baseline Characteristics of Heart Failure Cohort (n ¼ 720)
Overall TMAO <5 mM TMAO $5 mM p Value
Age, yrs 66  10 64  11 68  10 <0.001
Male 59 59 59 1.000
Diabetes mellitus 41 31 51 <0.001
Hypertension 78 76 79 0.316
Ischemic etiology 64 63 65 0.673
LV ejection fraction 35
(25–50)
35
(25–51)
40
(25–50)
0.567
Body mass index, kg/m2 28.4
(25.1–33.1)
28.7
(25.2–33.3)
28.1
(24.8–32.9)
0.298
Baseline medications
ACE inhibitors or ARBs 69 71 66 0.206
Beta-blockers 69 73 65 0.031
Loop diuretics 59 53 65 0.001
Statins 61 66 57 0.013
Aspirin 64 66 63 0.505
LDL cholesterol, mg/dl 91
(73–112)
93
(75–113)
88
(71–111)
0.069
HDL cholesterol, mg/dl 32
(26–40)
34
(27–42)
30
(25–38)
<0.001
BNP, pg/ml 294
(114–658)
226
(96–498)
358
(150–907)
<0.001
hsCRP, mg/l 3.9
(1.6–9.0)
2.9
(1.3–8.1)
3.4
(1.3–8.9)
0.585
eGFR, ml/min/1.73 m2 72
(56–87)
83
(70–93)
60
(44–74)
<0.001
TMAO, mM 5
(3.0–8.5)
3
(2.2–4)
8.5
(6.6–13.6)
<0.001
Values are mean  SD, %, or median (interquartile range).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; BNP ¼ B-type natriuretic peptide;
eGFR ¼ estimated glomerular ﬁltration rate; HDL ¼ high-density lipoprotein; hsCRP ¼ high-sensitivity C-reactive
protein; LDL ¼ low-density lipoprotein; LV ¼ left ventricular; TMAO ¼ trimethylamine-N-oxide.
TABLE 2
5-Year Al
Range
Unadjuste
Adjusted m
Adjusted m
Adjusted m
Model 1: ad
cholesterol,
adjusted fo
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1910receiver-operating characteristic curve (AUC) were
calculated according to mortality risk estimated
using Cox models adjusted for the above-mentioned
traditional risk factors with versus without TMAO,
as previously described (14,15). All analyses were
performed used R 2.15.1 (Vienna, Austria). A p value
<0.05 was considered statistically signiﬁcant.Hazard Ratio of Fasting Plasma TMAO Levels for
l-Cause Mortality
, mM
Quartile 1 Quartile 2 Quartile 3 Quartile 4
<3.03 3.03–5 5–8.51 $8.51
d 1 1.39
(0.87–2.24)
2.19
(1.39–3.43)*
3.42
(2.24–5.23)*
odel 1 1 1.17
(0.72–1.90)
1.44
(0.90–2.30)
2.20
(1.42–3.43)*
odel 2 1 1.14
(0.70–1.86)
1.33
(0.83–2.13)
1.75
(1.07–2.86)†
odel 3 1 1.18
(0.73–1.91)
1.34
(0.84–2.15)
1.85
(1.14–3.00)†
justed for traditional risk factors, including age, sex, systolic blood pressure, LDL
HDL cholesterol, smoking, diabetes mellitus, and BNP (log-transformed). Model 2:
r model 1 plus eGFR (log-transformed). Model 3: adjusted for model 2 plus hsCRP
rmed). *p < 0.01. †p < 0.05.
ions as in Table 1.RESULTS
BASELINE CHARACTERISTICS. We analyzed 720 pa-
tients with a history of HF fulﬁlling inclusion and
exclusion criteria. Baseline characteristics of our
study cohort are provided in Table 1. The median
TMAO level within the HF cohort was 5.0 mM (IQR:
3.0 to 8.5 mM), which was higher than that in the
healthy control cohort (3.5 mM; IQR: 2.3 to 5.7 mM;
p < 0.001) (Central Illustration). In our study cohort,
patients with elevated TMAO levels tended to be
older with a history of diabetes mellitus, renal
insufﬁciency, and lower HDL-C levels. Patients with
HF with higher TMAO levels were also more likely to
have higher BNP levels and diuretic use and lower
beta-blocker use. In contrast, history of hypertension,
ischemic etiology, left ventricular ejection fraction,
smoking history, body mass index, and sex were
similar across TMAO levels. Within the patients with
HF cohort, plasma TMAO levels were weakly but
signiﬁcantly inversely correlated with serum aryles-
terase activity (r ¼ 0.135; p < 0.001), a measure of
the antioxidant HDL-associated enzyme paraoxonase
1 (PON1) (12), and positively correlated with serum
uric acid levels (r ¼ 0.29; p < 0.001), which are asso-
ciated with pro-oxidant function (16,17).
FASTING PLASMA TMAO LEVELS AND MORTALITY
RISK. Over the 5-year follow-up, 207 deaths occurred
in our study cohort. Figure 1 represents the Kaplan-
Meier analysis of TMAO stratiﬁed by quartiles, which
illustrates a graded increased mortality risk that be-
comes particularly apparent when TMAO levels rise
higher than median levels. Importantly, elevated
TMAO levels were associated with increased mortality
risk within the HF cohort (quartile 4 vs. 1; HR: 3.42;
95% CI: 2.24 to 5.23; p < 0.001) (Table 2). As a contin-
uous variable, an increase in TMAO levels was associ-
ated with increased mortality risk at 5 years after
adjustment for traditional cardiac risk factors (HR:
1.18; 95% CI: 1.06 to 1.31 per SD; p < 0.01) (Table 2);
moreover, mortality risks were similar between
ischemic and nonischemic patients with HF, as well as
other clinical subgroups (Figure 2). Addition of TMAO
to a model of traditional cardiovascular risk factors
showed that elevated TMAO levels signiﬁcantly
improved net reclassiﬁcation (integrated discrimina-
tion improvement 16.0%; p < 0.001; net reclassiﬁca-
tion index 10.9%; p < 0.001) and trended toward
improvement in AUC (0.723 to 0.741; p ¼ 0.096).
ASSOCIATION BETWEEN TMAO AND CARDIORENAL
INDEXES IN MORTALITY RISK. We found relatively
modest but signiﬁcant correlation between TMAO
and BNP levels (r ¼ 0.23; p < 0.001) and stronger
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CENTRAL ILLUSTRATION Comparison of Fasting TMAO Levels Between Patients With Stable Heart Failure and
Apparently Healthy Controls
(Left) Trimethylamine-N-oxide (TMAO) concentration was higher in patients with stable heart failure than healthy controls and (Right)
portended poorer survival at higher levels regardless of B-type natriuretic peptide levels. Kaplan-Meier curves for 5-year all-cause mortality
with TMAO with TMAO/B-type natriuretic peptide (BNP) stratiﬁed at median levels.
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1911inverse correlation between TMAO levels and eGFR
(r ¼ 0.55; p < 0.001) in our study cohort. We further
investigated the association between TMAO levels
and cardiorenal indexes by constructing a model that
included BNP levels and eGFR. In this model, patients
in the highest quartile of TMAO (>8.5 mM) remained
at a signiﬁcantly higher mortality risk than those
with lower TMAO levels. Speciﬁcally, elevated fasting1.0
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FIGURE 1 Kaplan-Meier Estimates of Risk of All-Cause
Mortality According to Quartiles of Plasma Levels of TMAO
Kaplan-Meier curves for 5-year all-cause mortality with
trimethylamine-N-oxide (TMAO) stratiﬁed as quartiles.TMAO levels were associated with a 2.2-fold increase
in mortality risk after adjustment for traditional risk
factors and BNP levels (HR: 2.20; 95% CI: 1.42 to 3.43;
p < 0.01) and a 1.80-fold increase in mortality risk
even after adjustment for traditional risk factors
and BNP levels plus eGFR (HR: 1.75; 95% CI: 1.07 to
2.86; p < 0.05) and plus hsCRP levels (HR: 1.85; 95%
CI: 1.14 to 3.00; p < 0.05). Interestingly, within
the intermediate BNP range (second tertile 160 to
505 pg/ml), the lower 2 tertiles of TMAO portended a
3.3-fold increase in mortality risk (95% CI: 1.4 to 8;
p < 0.001), whereas the highest TMAO tertile (>7.2
mM) had a 5.7-fold increased mortality risk (95% CI:
2.5 to 13.2; p < 0.01) compared with both low BNP
and TMAO levels (Figure 3).
DISCUSSION
The key ﬁnding to our study is the strong prognostic
value of plasma TMAO levels in patients with stable
HF incremental to traditional risk factors, cardiorenal
indexes (BNP and eGFR), and markers of systemic
inﬂammation (hsCRP). It is intriguing that in the
setting of elevated natriuretic peptide levels, which
often represent signiﬁcant myocardial disease pro-
gression, a relatively low fasting TMAO level was
associated with far lower mortality risk than that seen
with elevated levels of both markers. These observa-
tions in a large population of HF patients further
Group
Age ≥ 65 years
Age < 65 years
Diabetes
Hypertension
No Hypertension
Male
Female
Cigarette smoker
Not Smoker
Prior CAD
0.1 1 10
Hazard Ratio
100
hsCRP < 2 mg/L
hsCRP ≥ 2 mg/L
No prior CAD
eGFR < 60 mL/min./1.73m2
eGFR ≥ 60 mL/min./1.73m2
No Diabetes
FIGURE 2 Relationship Between Plasma TMAO
Concentration and Mortality Risk Stratiﬁed According to
Baseline Characteristics
Forest plot of the hazard ratio (squares) of 5-year all-cause
mortality risk comparing ﬁrst and fourth quartiles of fasting
plasma TMAO levels. Bars represent 95% CI. The wide CI in some
subgroups are in part due to their small sample sizes and event
rates. CAD ¼ coronary artery disease; eGFR ¼ estimated
glomerular ﬁltration rate; hsCRP ¼ high-sensitivity C-reactive
protein; other abbreviation as in Figure 1.
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1912reﬁne the notion of a “gut hypothesis” and suggest
a potential association between the gut microbiota
pathway of known proatherogenic potential with
adverse prognosis in patients with HF.
Although TMAO has been shown to possess proa-
therogenic properties (10–12), which might partially
contribute to the adverse prognosis associated with
higher TMAO levels, the equivalent adverse prog-
nostic value of elevated TMAO levels in both ische-
mic and nonischemic HF suggests the possibility
that other potential mechanisms contribute to the
increased mortality risks observed in patients with
HF with elevated TMAO levels. Our recent identiﬁ-
cation of the host-microbiome relationship in forma-
tion of TMAO (10–12) has generated novel insights
into potential contributions of environmental factors
within the traditional deﬁnition of “self.” Although
the “gut hypothesis” in HF has prevailed over the
years, with evidence implying bacterial translocation
and heightened inﬂammatory responses and oxida-
tive stress, few studies have deﬁnitively linked
such associations with outcomes or directly demon-
strated such processes at the bedside. Our currentobservations therefore provided direct evidence
that accumulation in the systemic circulation of
TMAO, an obligatory downstream metabolite of gut
microbiota, heralds increased long-term adverse
clinical outcomes in patients with HF independently
of multiple cardiorenal indexes. It remains to be
determined whether elevated TMAO levels are
associated with enhanced gut edema and bacterial
translocation in HF; we have not identiﬁed an
alteration in the microbial composition within pa-
tients with HF at increased adverse prognosis as
the source of elevated TMAO levels among those
at increased mortality risk. In the setting of HF,
where ischemic or atherogenic processes appear less
important in long-term prognosis and progression,
the underlying mechanisms for the association be-
tween TMAO and adverse outcomes are not entirely
understood.
Clearly, other factors such as individual variations
in gut microbiota composition and impaired renal
clearance may inﬂuence systemic TMAO levels. The
notion that alterations in microbial composition and
gut microbial functional physiology may be part
of the HF syndrome is attractive (2). Changes in
bacterial composition have been shown to serve as
a primary driver of TMAO levels in other studies
(10,15). Whether microbial composition changes in
HF directly or indirectly contribute to enhanced
oxidative stress and inﬂammation is unclear, but we
did note that plasma TMAO levels were modestly
yet positively correlated with serum uric acid levels
and inversely correlated with PON1 activity as
monitored by serum arylesterase activity. Impor-
tantly, the association between TMAO levels and
eGFR was strong within our study cohort. How-
ever, we also observed that TMAO levels conferred
mortality risk prediction beyond traditional risk
factors, BNP, and eGFR, although the kidneys may
be physiologically impaired in eliminating TMAO
beyond eGFR.
The present study is the ﬁrst demonstration of
an association between elevated TMAO levels and
poor prognosis in patients with HF. Our ﬁndings
have several important implications that should be
discussed. First, by demonstrating the association
between TMAO and mortality risks in patients
with HF, our ﬁndings suggest that gut microbiota
composition and functional consequence may con-
tribute to disease progression during HF. With the
mechanistic link between TMAO and atherogenesis
in animal models (10,12), it is conceivable that pro-
gressive vascular remodeling and coronary athero-
genesis may occur in the setting of high TMAO
levels. Even in those with no known ischemic
60
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FIGURE 3 Mortality Rates Stratiﬁed by Tertiles of BNP and TMAO
Five-year mortality rates according to B-type natriuretic peptide (BNP) tertiles and
trimethylamine-N-oxide (TMAO) tertiles. All cohorts were signiﬁcantly different compared
with the reference cohort of BNP <160 pg/ml and TMAO <3.6 mM (all p < 0.01).
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1913heart disease, subclinical concomitant coronary ar-
tery disease may occur (18). In fact, previous au-
topsy ﬁndings have shown that progressive coronary
vasculopathy is not uncommon in patients with
HF nor is the occurrence of sudden cardiac death
(19). On the other hand, others have speculated that
there exists a potential link between progressive
wasting in advanced HF and other chronic disease
that can be associated with the gut microbiota
axis (20).
Second, the present studies suggest a potential
clinical utility for clearance of gut microbiome-
generated uremic toxins as a possible adjunct ther-
apy for HF. Of note, recent oral potassium binders
have shown some promise in clinical testing in pa-
tients with HF and cardiorenal compromise (21,22).
The ability of these interventions to eliminate harm-
ful compounds via the alimentary track remains un-
known. In the setting of advanced renal diseases,
direct binders have been reported to reduce levels
of indoxyl sulfate, a tryptophan-based gut micro-
biome metabolite that has shown antiatherosclerotic
effects in animal models (23). Hence, it is conceivable
that targeted interventions could directly impact
microbiome-host relationships, and further inves-
tigations are warranted into direct effects of TMAO
and other gut microbiome-derived metabolites on
cardiac remodeling.
STUDY LIMITATIONS. First, this was a single-center
study that recruited patients at the point of car-
diac evaluation for coronary angiography; hence,
selection bias may have identiﬁed a higher propor-
tion of patients with ischemic cardiomyopathy.
Also, this was a cohort of patients who underwent
elective coronary angiography; thus, right heart
catheterization was not performed in a large
majority of patients and was not readily available.
Also, because of this catchment, the large majority
of patients had relatively preserved renal function,
and few had advanced cardiorenal diseases or
advanced HF (annualized mortality of 5.8%). We
also did not have complete information regarding
New York Heart Association functional class, pres-
ence of cachexia, or atrial ﬁbrillation in our study
population, even though we believe that the inclu-
sion of BNP can integrate many of these risk pro-
ﬁles. Another potential limitation is that only a
single time-point blood draw after overnight fast
was available, and we did not have dietary history
to conﬁrm or refute the impact of diet on TMAO
levels or their cardiorenal consequences. Specif-
ically, we did not have any information regarding
gastrointestinal symptoms and pathology or priorantibiotic use or knowledge of prior supplements
other than those taken the day of enrollment. As in
most outcome studies, interim events and treatment
also may inﬂuence the primary outcome of all-cause
mortality.
Despite these limitations, our ﬁndings point to
novel insights that provide mechanistic links between
gut microbiota-associated metabolism involved in
TMAO formation and cardiorenal pathophysiology.
Further investigations to test the hypothesis that
targeted interventions are warranted to alter the gut
microbiota composition to lower TMAO production or
enhance TMAO clearance to determine whether it is
possible to alter the natural history of HF disease
progression.
CONCLUSIONS
Patients with HF had elevated TMAO levels compared
with those without HF. Elevated fasting TMAO levels
portended higher long-term mortality risk indepen-
dently of traditional risk factors, BNP levels, and
renal function.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
W.H. Wilson Tang, Cardiovascular Medicine, Cleve-
land Clinic, 9500 Euclid Avenue, Desk J3-4, Cleve-
land, Ohio 44195. E-mail: tangw@ccf.org.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The in-
testinal microbe-dependent metabolite, TMAO is related
to the pathogenesis of atherosclerosis and may play
a role in the development and progression of heart
failure.
TRANSLATIONAL OUTLOOK: Clinical studies should
address the effects of dietary modiﬁcations and other
interventions that alter microbe-generated intestinal
TMAO on the development and progression of heart
failure.
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